Please use this identifier to cite or link to this item:
https://hdl.handle.net/10216/151631| Author(s): | Morais, S Antunes, L Rodrigues, J Fontes, F Bento, MJ Lunet, N |
| Title: | The impact of the coronavirus disease 2019 pandemic on the diagnosis and treatment of cancer in Northern Portugal |
| Publisher: | Lippincott Williams and Wilkins |
| Issue Date: | 2022 |
| Abstract: | Objectives The coronavirus disease 2019 (COVID-19) pandemic has affected the availability of healthcare resources, and adjustments to cancer care have been necessary considering the risk of morbidity by COVID-19 and of cancer progression. This study aims to quantify the impact of the COVID-19 pandemic on the care of patients with cancer by comparing a period of 4 months after the outbreak began (2 March 2020) with an equal period from 2019. Methods Cancer cases of the esophagus, stomach, colon and rectum, pancreas, lung, skin-melanoma, breast, cervix, prostate, non-Hodgkin lymphoma, and leukemia from the Portuguese Oncology Institute of Porto, and diagnosed between 2 March and 1 July 2019 (before COVID-19) and 2020 (after COVID-19) were identified. Those with the first treatment outside the Portuguese Oncology Institute of Porto were excluded. Sociodemographic, clinical and treatment characteristics were obtained from the cancer registry database and clinical files. Results The absolute number of new cancer cases decreased nearly 40% after the COVID-19 pandemic (from 1430 to 866). The largest decreases were observed for cervical (-74.3%) and prostate (-71.7%) cancers. Cases were more often diagnosed at more advanced stages in 2020 (P = 0.001), and the proportion of patients not starting any treatment until 1 July was just under 20% in 2019 and nearly 40% in 2020. The median times from symptoms onset, first medical exam and first appointment to diagnosis, and from diagnosis to first appointment, multidisciplinary tumor board meeting and first treatment were shorter after COVID-19. Conclusions There was a notable overall decrease in cancer diagnoses after COVID-19, with changes in the characteristics of incident cases. © 2022 Lippincott Williams and Wilkins. All rights reserved. |
| Subject: | cancer; COVID-19; Health Services Research; pandemic; treatment |
| DOI: | 10.1097/CEJ.0000000000000686 |
| URI: | https://hdl.handle.net/10216/151631 |
| Source: | Eur J Cancer Prev. 2022 Mar 1;31(2):204-214. doi: 10.1097/CEJ.0000000000000686. |
| Related Information: | info:eu-repo/grantAgreement/FCT/9471 - RIDTI/PTDC/SAU-EPI/32358/2017/PT info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB/04750/2020/PT |
| Document Type: | Artigo em Revista Científica Internacional |
| Rights: | openAccess |
| License: | https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Appears in Collections: | ISPUP - Artigo em Revista Científica Internacional |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| morais-ejcp-2022.pdf | 1.09 MB | Adobe PDF | ![]() View/Open |
This item is licensed under a Creative Commons License
